Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(1.06) per share which beat the analyst consensus estimate of $(1.14) by 7.02 percent. This is a 27.89 percent increase over losses of $(1.47) per share from the same period last year. The company reported quarterly sales of $14.93 million which missed the analyst consensus estimate of $15.95 million by 6.43 percent. This is a 12.48 percent decrease over sales of $17.05 million the same period last year.